Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The FDA and the case of Ketek.

× No keyword cloud information.

29 in total

1. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.

Authors: J Gordon Still; Jennifer Schranz; Thorsten P Degenhardt; Drusilla Scott; Prabhavathi Fernandes; Maria J Gutierrez; Kay Clark
Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191

2. Medicine. Moving toward transparency of clinical trials.

Authors: Deborah A Zarin; Tony Tse
Journal: Science Date: 2008-03-07 Impact factor: 47.728

3. Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors: Russell G Thornton
Journal: Proc (Bayl Univ Med Cent) Date: 2008-01

4. Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions.

Authors: Yoshinari Wakiyama; Ko Kumura; Eijiro Umemura; Satomi Masaki; Kazutaka Ueda; Yasuo Sato; Yoko Hirai; Yoshio Hayashi; Keiichi Ajito
Journal: J Antibiot (Tokyo) Date: 2017-11-01 Impact factor: 2.649

5. Macrolones Are a Novel Class of Macrolide Antibiotics Active against Key Resistant Respiratory Pathogens In Vitro and In Vivo.

Authors: Hana Čipčić Paljetak; Donatella Verbanac; Jasna Padovan; Miroslava Dominis-Kramarić; Željko Kelnerić; Mihaela Perić; Mihailo Banjanac; Gabrijela Ergović; Nerrisa Simon; John Broskey; David J Holmes; Vesna Eraković Haber
Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191

6. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.

Authors: Patricia M Roblin; Stephan A Kohlhoff; Charles Parker; Margaret R Hammerschlag
Journal: Antimicrob Agents Chemother Date: 2009-12-28 Impact factor: 5.191

7. Combating antimicrobial resistance: policy recommendations to save lives.

Authors: Brad Spellberg; Martin Blaser; Robert J Guidos; Helen W Boucher; John S Bradley; Barry I Eisenstein; Dale Gerding; Ruth Lynfield; L Barth Reller; John Rex; David Schwartz; Edward Septimus; Fred C Tenover; David N Gilbert
Journal: Clin Infect Dis Date: 2011-05 Impact factor: 9.079

8. "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs.

Authors: Shirley V Wang; Sebastian Schneeweiss; Malcolm Maclure; Joshua J Gagne
Journal: Am J Epidemiol Date: 2014-08-01 Impact factor: 4.897

9. Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.

Authors: John K Chan; Tuyen K Kiet; Bradley J Monk; Nichole Young-Lin; Kevin Blansit; Daniel S Kapp; Idoroenyi Amanam
Journal: Oncologist Date: 2014-03-05

Review 10. Clinical trial design and selected drug safety issues for antibiotics used to treat community-acquired pneumonia.

Authors: Bruce M Psaty
Journal: Clin Infect Dis Date: 2008-12-01 Impact factor: 9.079